Company: CERO
Filing Date: 2025-02-07
Form Type: 424B3
Source: 0001213900-25-011071
Chunk: 40

Company: CERO THERAPEUTICS HOLDINGS, INC.
Filing Date: 2025-02-07
Form: 424B3
Chunk 40
---
 difficulties
in patient enrollment in our clinical trials for a variety of reasons. The timely completion of clinical trials in accordance with their
protocols depends, among other things, on our ability to enroll a sufficient number of patients who remain in the study until its conclusion.
The enrollment of patients depends on many factors, including:

| ● | the patient eligibility           
 criteria defined in the protocol; |

| ● | the number of patients                       
 with the disease or condition being studied; |

| ● | the perceived risks and                         
 benefits of the product candidate in the trial; |

| ● | clinicians’ and patients’                                                                                                              
 perceptions as to the potential advantages of the product candidate being studied in relation to other available therapies, including  
 any new drugs that may be approved for the indications we are investigating or drugs that may be used off-label for these indications; |

| ● | the size and nature of the patient population required for analysis of the trial’s primary and secondary endpoints; |

| ● | the proximity of patients 
 to study sites;           |

| ● | the design of the clinical 
 trial;                     |

| ● | our ability to recruit                                                         
 clinical trial investigators with the appropriate competencies and experience; |

<div align='center'>17</div>

| ● | competing clinical trials                                                                 
 for similar therapies or other new therapeutics not involving T cell-based immunotherapy; |

| ● | our ability to obtain and  
 maintain patient consents; |

| ● | the risk that patients                                                                                     
 enrolled in clinical trials will drop out of the clinical trials before completion of their treatment; and |

| ● | other public health factors,                                         
 including the coronavirus pandemic or outbreaks of other infections. |

In particular, some of our
clinical trials will look to enroll patients with characteristics which are found in a very small population. For example, our clinical
trial for CER-1236 will seek to enroll patients with hematologic malignancies, including AML, MCL, CLL, and other B cell and myeloid
neoplasms. Other companies are conducting clinical trials with their engineered T cell therapies in hematologic malignancies and seek
to enroll patients in their studies that may otherwise be eligible for our clinical trials, which could lead to slow recruitment and
delays in our clinical trials. In addition, since the number of qualified clinical investigators is limited, we expect to conduct some
of our clinical trials at the same clinical trial sites that some of our competitors use, which could further reduce the number of patients
who are available for